Navigation Links
Albireo Announces Positive Clinical Data on A3309 in Patients with Chronic Idiopathic Constipation
Date:11/18/2009

GOTHENBURG, Sweden, November 18 /PRNewswire/ -- Albireo today announced the completion of a phase 1b study showing a favorable tolerability and safety profile of A3309 in patients with chronic idiopathic constipation. In addition, the data revealed appropriate efficacy signals in this patient population. A3309 is a first in class compound developed for the treatment of chronic idiopathic constipation and constipation-predominant Irritable Bowel Syndrome (IBS-C). Based on these results, Albireo expects to recruit 180 patients with chronic idiopathic constipation in a US phase 2b study (http://www.clinicaltrials.gov) under an IND recently placed into effect by the FDA.

Notes for Editors:

About CIC

Constipation is one of the most common gastrointestinal complaints. Chronic idiopathic constipation is a more severe and disabling disease, which is not effectively managed by current treatment options. More than 4 million Americans have chronic constipation resulting in 9 million physician visits annually and in addition lead to more than 92,000 hospitalizations annually. In a survey study of 557 individuals with chronic constipation, 47% of respondents indicated a lack of satisfaction with treatment (82% citing lack of treatment efficacy as the reason for dissatisfaction).

About A3309

A3309 is a therapeutic alternative with a novel mechanism of action developed for the treatment of chronic idiopathic constipation and constipation-predominant Irritable Bowel Syndrome (IBS-C). A3309 modulates the re-uptake of bile acids by inhibiting the ileal bile acid transporter. This will result in an increased concentration of bile acids in the colon which, in turn, increase fluid secretion and colonic motility. These physiological responses should provide benefits to patients with chronic constipation and IBS-C without any effects on other parts of the gastrointestinal tract.

About Albireo

Albireo is an independent Swedish biotechnology company focused on the development of novel therapeutic alternatives to fulfill medical needs in the gastrointestinal area. Albireo was spun-out of AstraZeneca in February 2008 and is financed by a syndicate of growth capital firms, including Nomura Phase4 Ventures, TPG growth, TVM Capital and Scottish Widows Investment Partnership. The company has raised $40m in its Series A financing round (http://www.albireopharma.com).

SOURCE Albireo


'/>"/>
SOURCE Albireo
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
2. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
3. UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West
4. HEI, Inc. Announces Sale of RFID Division Assets
5. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
6. Mettler-Toledo International Inc. Announces Webcast of Presentation at Thomas Weisel Partners 2007 Healthcare Conference
7. Z Trim Announces Revocation of Gregory Halpern Severence Agreement
8. Brooke Franchise Corporation Announces Selected July Results
9. Manor Care, Inc. Announces Record Date for Special Stockholder Meeting
10. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
11. Planet Technologies Announces Agreement to Acquire Antigen Laboratories
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... ... January 18, 2017 , ... Rollerblade®, ... Brake Technology (ABT), an innovative braking system that allows skaters of all levels ... one of the biggest concerns of beginner and intermediate skaters – learning how ...
(Date:1/18/2017)... ... , ... Floundering on New Year’s resolutions? Need an excuse to get back ... The U.S. Apple Association agrees and recommends starting each day with apples, a ... heart disease. , The U.S. Apple Association – which represents apple growers and producers ...
(Date:1/17/2017)... ... ... Anesthesia Progress – Everyone wants less pain during dental surgery, but ... patient. Dentists have several general anesthesia alternatives and finding the right option can result ... College in Tokyo, Japan wanted to find out which anesthetic was the better choice ...
(Date:1/17/2017)... ... January 17, 2017 , ... ... of difference. Eden Activewear is a stand-out company for several differences from other ... and only manufacture on demand, this is called 'Agile' manufacturing - http://www.leanproduction.com/agile-manufacturing.html ...
(Date:1/17/2017)... ... January 17, 2017 , ... Today, to ... Carol Francis re-releases powerfully uplifting interview with medical expert and prolific author, Dr. ... and pass through tough times, Dr. Bernie Siegel energizes listeners to live life ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... 2017   Synthetic Biologics, Inc. (NYSE ... designed to preserve the microbiome to protect and ... to initiate a Phase 2b/3 adaptive pivotal trial ... lactone designed to reduce methane production by certain ... to treat the underlying cause of irritable bowel ...
(Date:1/18/2017)...  Aprima Medical Software, a leading provider of ... and revenue cycle management (RCM) solutions for medical ... reseller Healthcare Data Solutions (HDS) of Coral Cables, ... assume full support for HDS,s customers, which include ... 15 states. Financial terms were not disclosed. ...
(Date:1/18/2017)... Jan. 18, 2017   Spotlight Innovation Inc. ... Therapeutics plans, in the second quarter of 2017, ... roll-on intended to provide relief from chronic pain, ... analgesics. It was developed under a licensing agreement ... products derived from snake venom. Additionally, Caretta Therapeutics ...
Breaking Medicine Technology: